fashion -WSS

fashion

author：Wikipedia 2025-10-01 00:59:53 - browse：25

Elf Bar disposable vape flavored vaping e-cigarette products are displayed in a convenience store. — The FDA is ramping up its efforts to force vape shops and other retailers to stop selling Elf Bar and Esco Bar products. PATRICK T. FALLON/AFP via Getty Images

WASHINGTON — The Food and Drug Administration is ramping up its efforts to force vape shops and other retailers to stop selling unauthorized disposable vape brands that are increasingly popular with young people.

The FDA recently issued 189 formal warning letters to shops selling two brands of vape products, Elf Bar and Esco Bars, the agency announced in a press release Thursday. The FDA has not authorized either brand, both of which are ubiquitous in gas stations and smoke shops around the country. They are therefore illegal to sell.

“This latest blitz should be a wake-up call for retailers of Elf Bar and Esco Bars products nationwide,” said Brian King, the head of the FDA’s tobacco center in a statement announcing the blitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Anthos stroke drug appears safer than common blood thinner

WSS

Wegovy, Zepbound and weight loss drugs that preserve muscle

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Astellas still sees hope in its gene therapy after four deaths

Unmasking the 'centricity' illusion in clinical trials

Hospitals need to get ahead of regulations on climate change

Congress must reauthorize a committee to support older Americans

knowledge

fashion

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A daunting task: navigating dual Medicare, Medicaid eligibility

Alkermes shareholders re

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Activists slam private health insurers over coverage restrictions

A daunting task: navigating dual Medicare, Medicaid eligibility

Alkermes shareholders re

Hospitals look to new technology to keep health care workers safe

leisure time

Stroke rates rising, especially in working

Guardant Health colon cancer test endorsed by FDA advisory panel

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Some medical students still think black patients feel less pain

CRISPR pioneers react to Casgevy, first gene

focus

focus

focus

focus